Abstract Cyclin-dependent kinase (CDK) 4/6 inhibition in combination with endocrine
therapy is the standard-of-care treatment for patients with advanced-stage hormone receptor …

Abstract The cyclin-dependent kinase 4/6 inhibitors (CDK4/6i) have become the standard of
care, in combination with antiestrogen therapy, for patients with hormone receptor–positive …

PURPOSE Cyclin-dependent kinase 4/6 inhibitor (CDK4/6i) with endocrine therapy (ET)
improves progression-free survival (PFS) and overall survival (OS) in hormone receptor …

The natural history of hormone receptor–positive breast cancer tends to be more favorable
than other subtypes such as human epidermal growth factor receptor 2–amplified and triple …

Cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitors have revolutionized the treatment of
hormone-positive metastatic breast cancers (mBCs). They are currently established as …

In the past decade, significant progress was made in treating hormone receptor-positive
(HR+), human epidermal growth factor receptor 2-negative (HER2−) metastatic breast …

CDK4/6 inhibitors have become game-changers in the treatment of estrogen receptor-
positive (ER+) breast cancer, and in combination with endocrine therapy are the standard of …

Anti-oestrogen-based therapies, often combined with a CDK4/6 inhibitor, are the current
standard-of-care first-line therapy for patients with advanced-stage hormone receptor …

Background Acquired ESR1 mutations in estrogen receptor-positive (ER+) metastatic breast
cancer (mBC) drive treatment resistance and tumor progression; new treatment strategies …

Background Metastatic hormone receptor positive (HR+)/human epidermal growth factor
receptor-2 negative (Her2−) breast cancer remains a significant cause of cancer-related …